441 related articles for article (PubMed ID: 25418218)
1. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
[TBL] [Abstract][Full Text] [Related]
2. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
[TBL] [Abstract][Full Text] [Related]
3. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial.
Liu J; Xie Y; He F; Gao Z; Hao Y; Zu X; Chang L; Li Y
Biomed Res Int; 2016; 2016():5985327. PubMed ID: 26949703
[TBL] [Abstract][Full Text] [Related]
5. Association of N-terminal pro-B-type natriuretic peptide with contrast-induced nephropathy and long-term outcomes in patients with chronic kidney disease and relative preserved left ventricular function.
Liu YH; Liu Y; Zhou YL; Yu DQ; He PC; Xie NJ; Li HL; Wei-Guo ; Chen JY; Tan N
Medicine (Baltimore); 2015 Apr; 94(13):e358. PubMed ID: 25837748
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
7. Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI.
Xing K; Fu X; Wang Y; Li W; Gu X; Hao G; Miao Q; Li S; Jiang Y; Fan W; Geng W
Heart Vessels; 2016 Apr; 31(4):490-8. PubMed ID: 25637044
[TBL] [Abstract][Full Text] [Related]
8. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
9. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
[TBL] [Abstract][Full Text] [Related]
11. Sodium bicarbonate versus isotonic saline for the prevention of contrast-induced nephropathy in patients with diabetes mellitus undergoing coronary angiography and/or intervention: a multicenter prospective randomized study.
Koc F; Ozdemir K; Altunkas F; Celik A; Dogdu O; Karayakali M; Gul EE; Erkorkmaz U; Kadi H; Akpek M; Kaya MG
J Investig Med; 2013 Jun; 61(5):872-7. PubMed ID: 23552179
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
13. [The use of recombinant human B-type natriuretic peptide for the protection of cardiac and renal functions in heart failure patients with acute anterior myocardial infarction in peri-operative period of primary percutaneous coronary intervention].
Zhang J; Fu XH; Fan XN; Jia XW; Gu XS; Li SQ; Jiang YF; Fan WZ; Su JL
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Nov; 22(11):669-73. PubMed ID: 21122202
[TBL] [Abstract][Full Text] [Related]
14. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
[TBL] [Abstract][Full Text] [Related]
15. Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.
Capodanno D; Ministeri M; Cumbo S; Dalessandro V; Tamburino C
Catheter Cardiovasc Interv; 2014 May; 83(6):907-12. PubMed ID: 23934631
[TBL] [Abstract][Full Text] [Related]
16. The influence of contrast media on kidney function in patients with stable coronary artery disease.
Reuter SB; Harutyunyan M; Mygind ND; Jørgensen E; Kastrup J
Scand Cardiovasc J; 2014 Aug; 48(4):234-40. PubMed ID: 24941300
[TBL] [Abstract][Full Text] [Related]
17. Alpha-lipoic acid for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography: the ALIVE study - a prospective randomized trial.
Jo SH; Kim SA; Kim HS; Han SJ; Park WJ; Choi YJ
Cardiology; 2013; 126(3):159-66. PubMed ID: 23988855
[TBL] [Abstract][Full Text] [Related]
18. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
19. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
[TBL] [Abstract][Full Text] [Related]
20. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
